{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:36:56Z","timestamp":1790267816728,"version":"4.1.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-drug interactions (DDIs) may influence the effectiveness and safety of medication treatment, which may require additional monitoring, dose adjustment or avoidance of certain drugs. DDIs involving P-glycoprotein (P-gp) affect many drugs, but current official product information is often insufficient to guide the management of these DDIs in clinical practice. The aim of this paper is to describe a protocol to assess DDIs involving P-gp and to develop and implement practice recommendations for clinically relevant P-gp-mediated DDIs that affect clinical outcomes through changes in systemic drug exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A combined literature review and expert opinion approach will be used according to the following seven steps: set up an expert panel (step 1), establish core concepts and definitions (step 2), select potential P-gp-modulators (i.e., P-gp-inducers and -inhibitors) and P-gp-substrates to be evaluated (step 3), select and extract evidence-based data, and present findings in standardized assessment reports (step 4), discuss and adopt classifications and practice recommendations with the expert panel (step 5), publish and integrate information and alerts in clinical decision support systems (CDSS) (step 6), (re)assessments of DDIs and potential new DDIs when new information is available or when initiated by healthcare providers (step 7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Anticipated results<\/jats:title><jats:p>The expert panel will classify potential P-gp-modulators and -substrates as clinically relevant P-gp-inducer, -inhibitor and\/or -substrate and draw conclusions about which combinations of classified modulators and substrates will lead to clinically relevant DDIs. This may include the extrapolation of conclusions for DDIs where limited or no data are available, based on the pharmacological characteristics of these drugs. For (potential) DDIs that are considered to be clinically relevant, practice recommendations will be developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This protocol describes a standardized, evidence- and expert opinion-based assessment of P-gp-mediated DDIs that affect clinical outcomes. This approach will generate alerts with practice recommendations for clinically relevant DDIs and transparent rationales for DDIs that are considered to be irrelevant. These recommendations will improve individual patient care by supporting healthcare professionals to make consistent decisions on how to manage P-gp mediated DDIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1412692","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:37:11Z","timestamp":1727689031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions"],"prefix":"10.3389","volume":"15","author":[{"given":"Leonie","family":"Bogaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayan","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"van de Steeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther F. A.","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"Geers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet","family":"van Herwaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margje","family":"Monster-Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S. Y.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander D.","family":"Borgsteede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"595219","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1365-2125.2011.04106.x","article-title":"Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers","volume":"73","author":"Akamine","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/dti.S12519","article-title":"P-Glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"key":"B4","volume-title":"The renal drug handbook","author":"Ashley","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.2766","article-title":"Contribution of real-world evidence in European medicines agency's regulatory decision making","volume":"113","author":"Bakker","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B6","volume-title":"Stockleys interactions checker","author":"Baxter","year":"2024"},{"key":"B7","volume-title":"Drug transporter proteins","author":"Baxter","year":"2018"},{"key":"B8","unstructured":"MDR1\/P-gp\n            BiotechnologyS.\n          2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/pharmaceutics13020266","article-title":"Drug-drug interactions in elderly patients with potentially inappropriate medications in primary care, nursing home and hospital settings: a systematic review and a preliminary study","volume":"13","author":"Bories","year":"2021","journal-title":"Pharmaceutics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/clpt.2014.83","article-title":"Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots","volume":"96","author":"Bosilkovska","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/jcph.2316","article-title":"What the product label does not tell you about drug-drug interaction management: time for a Re-appraisal","volume":"63","author":"Burger","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/0897190017699138","article-title":"Comorbidity, polytherapy, and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs","volume":"31","author":"Busa","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"B13","year":"2024","journal-title":"Health Base Found"},{"key":"B14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejps.2008.11.005","article-title":"In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption","volume":"36","author":"del Amo","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s11096-021-01308-0","article-title":"Management of drug-disease interactions: a best practice from The Netherlands","volume":"43","author":"Diesveld","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"B16","first-page":"108","article-title":"Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment","volume":"11","author":"Dorian","year":"1988","journal-title":"Clin. Invest Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, Part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"Duran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B19","volume-title":"Vijay ivaturi","author":"Elyes Dahmane","year":"2024"},{"key":"B20","unstructured":"Guideline on the investigation of bioequivalence2010"},{"key":"B21","unstructured":"Guideline on the investigation of drug interactions2012"},{"key":"B22","article-title":"EPAR - product information","year":"2024","journal-title":"EMA Product. Inf. EN"},{"key":"B23","unstructured":"Clinical drug interaction studies - cytochrome P450 enzyme- and transporter-mediated drug interactions january 2020"},{"key":"B24","unstructured":"Vitro drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions"},{"key":"B25","unstructured":"For healthcare professionals | FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems - table 1: CYP enzyme- and transporter system-based clinical substrates, inhibitors, or inducers2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00228-013-1612-7","article-title":"Checklist for standardized reporting of drug-drug interaction management guidelines","volume":"70","author":"Floor-Schreudering","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical aspects of transporter-mediated drug-drug interactions","volume":"105","author":"Gessner","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/jamia\/ocae076","article-title":"The use of artificial intelligence to optimize medication alerts generated by clinical decision support systems: a scoping review","volume":"31","author":"Graafsma","year":"2024","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B29","year":"2024"},{"key":"B30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1067\/mcp.2001.113697","article-title":"The effect of rifampin administration on the disposition of fexofenadine","volume":"69","author":"Hamman","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.clinthera.2021.08.016","article-title":"Analysis of drug-drug interaction labeling language and clinical recommendations for newly approved drugs evaluated with digoxin, midazolam, and S-warfarin","volume":"43","author":"Henderson","year":"2021","journal-title":"Clin. Ther."},{"key":"B32","unstructured":"PharmGKB. Very important Pharmacogene: ABCB1. Latst updated: 06\/26\/2024\n            HodgesL. M.\n            MarkovaS. M.\n            ChinnL. W.\n            GowJ. M.\n            KroetzD. L.\n            KleinT. E.\n          2024"},{"key":"B33","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Drug Interaction Studies M12 - final version2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"101008","DOI":"10.1016\/j.dmpk.2024.101008","article-title":"Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery","volume":"56","author":"Kido","year":"2024","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/jpm12040526","article-title":"Impact of the genotype and phenotype of CYP3A and P-gp on the apixaban and rivaroxaban exposure in a real-world setting","volume":"12","author":"Lenoir","year":"2022","journal-title":"J. Pers. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/17425255.3.1.81","article-title":"Transporter-mediated drug interactions: clinical implications and in vitro assessment","volume":"3","author":"Lin","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40265-017-0729-x","article-title":"Clinical implications of P-glycoprotein modulation in drug-drug interactions","volume":"77","author":"Lund","year":"2017","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1072","article-title":"Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.clinthera.2021.12.010","article-title":"Real-world data in the postapproval setting as applied by the EMA and the US FDA","volume":"44","author":"Mofid","year":"2022","journal-title":"Clin. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"B44","volume-title":"The Oxford 2011 levels of evidence","year":"2011"},{"key":"B45","doi-asserted-by":"publisher","first-page":"220004","DOI":"10.1183\/16000617.0004-2022","article-title":"Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer","volume":"31","author":"Otten","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/cts.13449","article-title":"Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services","volume":"16","author":"Pasternak","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/amiajnl-2012-001089","article-title":"Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records","volume":"20","author":"Phansalkar","year":"2013","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B49","unstructured":"PharmaPartners2018"},{"key":"B50","volume-title":"Version 6.1.3","year":"2024"},{"key":"B51","volume-title":"UpToDate - drug interactions","author":"Post","year":"2024"},{"key":"B52","volume-title":"Novartis, EMA product information (NL)","year":"2023"},{"key":"B53","unstructured":"Huisartsen werken vaker in loondienst en in groepspraktijk (PW3)2023"},{"key":"B54","article-title":"EPAR - product information","year":"2023","journal-title":"EMA Product. Inf. EN"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1177\/0091270010385934","article-title":"Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects","volume":"51","author":"Rebello","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","article-title":"Dose optimization informed by PBPK modeling: state-of-the art and future","volume":"116","author":"Rowland Yeo","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B58","unstructured":"Aantal apotheken zakt terug naar niveau 2008 (PW7)2008"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/europace\/euab218","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment-Authors' reply","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B60","article-title":"EPAR - product information","year":"2024","journal-title":"EMA Product. Inf. En"},{"key":"B61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cpt.2670","article-title":"Clinical relevance of hepatic and renal P-gp\/BCRP inhibition of drugs: an international transporter Consortium perspective","volume":"112","author":"Taskar","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fphar.2020.00420","article-title":"Precision dosing priority criteria: drug, disease, and patient population variables","volume":"11","author":"Tyson","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/00498254.2014.928958","article-title":"Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information","volume":"44","author":"Umeyama","year":"2014","journal-title":"Xenobiotica"},{"key":"B65","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1197\/jamia.M1809","article-title":"Overriding of drug safety alerts in computerized physician order entry","volume":"13","author":"van der Sijs","year":"2006","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.seminoncol.2022.03.002","article-title":"Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management","volume":"49","author":"van Leeuwen","year":"2022","journal-title":"Semin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2165\/00002018-200528120-00007","article-title":"Clinical relevance of drug-drug interactions: a structured assessment procedure","volume":"28","author":"van Roon","year":"2005","journal-title":"Drug Saf."},{"key":"B68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fphar.2020.00707","article-title":"The development of practice recommendations for drug-disease interactions by literature review and expert opinion","volume":"11","author":"van Tongeren","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.3390\/molecules28227532","article-title":"Study models of drug-drug interactions involving P-glycoprotein: the potential benefit of P-glycoprotein modulation at the kidney and intestinal levels","volume":"28","author":"Veiga-Matos","year":"2023","journal-title":"Molecules"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1093\/jac\/dkz221","article-title":"Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients","volume":"74","author":"Wang","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/17425255.2012.685237","article-title":"Role of CAR and PXR in xenobiotic sensing and metabolism","volume":"8","author":"Wang","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e012991","DOI":"10.1136\/bmjopen-2016-012991","article-title":"Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion","volume":"6","author":"Weersink","year":"2016","journal-title":"BMJ Open"},{"key":"B73","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40264-017-0635-x","article-title":"Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis","volume":"41","author":"Weersink","year":"2018","journal-title":"Drug Saf."},{"key":"B74","volume-title":"QTdrugs list","author":"Woosley","year":"2013"},{"key":"B75","article-title":"Public consultation: new classification of L04A immunosuppressants","year":"2022","journal-title":"ATC Classif. - Propos. 1 - L04A Immunosuppr"},{"key":"B76","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/FTD.0b013e3181bf7db6","article-title":"Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics","volume":"31","author":"Yamada","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"B77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/psp4.55","article-title":"Organ impairment-drug-drug interaction database: a tool for evaluating the impact of renal or hepatic impairment and pharmacologic inhibition on the systemic exposure of drugs","volume":"4","author":"Yeung","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/cpt.28","article-title":"Novel bioequivalence approach for narrow therapeutic index drugs","volume":"97","author":"Yu","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cpt.1916","article-title":"Intestinal P-gp and putative hepatic OATP1B induction: international transporter Consortium perspective on drug development implications","volume":"109","author":"Zamek-Gliszczynski","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/cpt.1214","article-title":"Transporters in drug development: scientific and regulatory considerations","volume":"104","author":"Zhang","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cpt.2988","article-title":"Clinical pharmacology applications of real-world data and real-world evidence in drug development and approval-an industry perspective","volume":"114","author":"Zhu","year":"2023","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1412692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:37:21Z","timestamp":1727689041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1412692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":81,"alternative-id":["10.3389\/fphar.2024.1412692"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1412692","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1412692"}}